Conference Coverage

Survival after TAVR superior to surgery in high-risk aortic stenosis patients


 

FROM ACC14

The study was published simultaneously in the New England Journal of Medicine on March 29 (2014 March 29 [doi:10.1056/NEJMoa1400590]).

The study is funded by the CoreValve manufacturer, Medtronic. Dr. Adams disclosed receiving grant support from Medtronic during the conduct of the study and other support from Medtronic and Edwards Lifesciences outside the submitted work.

emechcatie@frontlinemedcom.com

Pages

Recommended Reading

Inpatient safety efforts yield mixed results
MDedge Family Medicine
CoreValve holds size advantage for U.S. TAVR
MDedge Family Medicine
Latest heart failure guidelines break new ground
MDedge Family Medicine
FDA to probe saxagliptin’s heart failure risk
MDedge Family Medicine
Mini-VADs could transform heart failure therapy
MDedge Family Medicine
PITCH is called for a balk
MDedge Family Medicine
Medicare to cover cardiac rehab for some HF patients
MDedge Family Medicine
HFPEF’s diverse features pose management and trial challenges
MDedge Family Medicine
Physician/patient communication on ICDs deemed problematic
MDedge Family Medicine
Higher MAP target fails to improve sepsis survival
MDedge Family Medicine

Related Articles